Cochrane Abstracts
Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow‐responder adult patients
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Extended Peginterferon Plus Ribavirin Treatment for 72 Weeks Versus Standard Peginterferon Plus Ribavirin Treatment for 48 Weeks in Chronic Hepatitis C Genotype 1 Infected Slow‐responder Adult Patients." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/439804/all/Extended_peginterferon_plus_ribavirin_treatment_for_72_weeks_versus_standard_peginterferon_plus_ribavirin_treatment_for_48_weeks_in_chronic_hepatitis_C_genotype_1_infected_slow‐responder_adult_patients.
Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow‐responder adult patients. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/439804/all/Extended_peginterferon_plus_ribavirin_treatment_for_72_weeks_versus_standard_peginterferon_plus_ribavirin_treatment_for_48_weeks_in_chronic_hepatitis_C_genotype_1_infected_slow‐responder_adult_patients. Accessed March 19, 2025.
Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow‐responder adult patients. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/439804/all/Extended_peginterferon_plus_ribavirin_treatment_for_72_weeks_versus_standard_peginterferon_plus_ribavirin_treatment_for_48_weeks_in_chronic_hepatitis_C_genotype_1_infected_slow‐responder_adult_patients
Extended Peginterferon Plus Ribavirin Treatment for 72 Weeks Versus Standard Peginterferon Plus Ribavirin Treatment for 48 Weeks in Chronic Hepatitis C Genotype 1 Infected Slow‐responder Adult Patients [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 March 19]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/439804/all/Extended_peginterferon_plus_ribavirin_treatment_for_72_weeks_versus_standard_peginterferon_plus_ribavirin_treatment_for_48_weeks_in_chronic_hepatitis_C_genotype_1_infected_slow‐responder_adult_patients.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow‐responder adult patients
ID - 439804
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/439804/all/Extended_peginterferon_plus_ribavirin_treatment_for_72_weeks_versus_standard_peginterferon_plus_ribavirin_treatment_for_48_weeks_in_chronic_hepatitis_C_genotype_1_infected_slow‐responder_adult_patients
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
